31.05.2007

"We applaud our marketing partner's success in securing FDA approval of the only twice-daily leukotriene synthesis inhibitor for asthma"

Dey, L.P. announced today that the U.S. Food and Drug Administration has approved the New Drug Application of its marketing partner, Critical Therapeutics, Inc. via P&T Community


Leave a Reply